This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dejaco C et al. (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in RA. Arthritis Res Ther 19: R119
Ménard HA et al. (2000) Insights into RA derived from the Sa immune system. Arthritis Res Ther 2: 429–432
Boire G et al. (2005) Anti-Sa antibodies and antibodies against CCP are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7: R592–603
Asaga H et al. (1998) Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 243: 641–646
Hill JS et al. (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171: 538–541
Auger I et al. (2005) Influence of HLA-DR genes on the production of RA-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52: 3424–3432
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ménard, H. Anti-CCP versus anti-Sa antibodies for the diagnosis of RA. Nat Rev Rheumatol 3, 76–77 (2007). https://doi.org/10.1038/ncprheum0401
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0401